摘要
目的:研究萎胃散治疗慢性萎缩性胃炎(CAG)的疗效及其机制。方法:将SD大鼠分为5组,即正常对照组、模型组与萎胃散高、低剂量组及维酶素组。正常对照组大鼠仅予生理盐水灌胃;用主动免疫法及阿司匹林、乙醇、去氧胆酸钠灌胃同时造大鼠CAG模型;造模后治疗组大鼠以萎胃散高、低剂量治疗60d,以胃黏膜固有腺体萎缩程度为观察指标,判断萎胃散疗效。结果:与模型组比较,萎胃散高、低剂量及维酶素组大鼠的CAG病变状况显著好转(P<0.05),病理检查可见腺体恢复正常。结论:萎胃散可使胃黏膜固有腺体增多,对CAG有良好的治疗作用。
OBJECTIVE: To study the curative efficacy and the mechanism of Weiwei san in treating chronic atrophic gastritis (CAG). METHODS: SD rats were divided into 5 groups:normal control group, model group, Weimeisu group, high dose Weiwei san group, and low dose Weiwei san group .The normal control group was administered intragastrically with normal sodium only; CAG model was established in rats by intragastric administration with active immunity,Aspirin, alcohol,and sodium deoxycholate simultaneously. Then the rats in the treatment groups were treated with Weiwei san (high dose or low dose) for 60 days. The atrophic degree of the intrinsic gastromucosal gland was taken as the primary outcome to evaluate the efficacy of Weiwei san. RESULTS: As compared with the model group, the CAG in high and low doses Weiwei san groups and Weimeisu group improved significantly (P〈0.05), and on pathological examination, the their gastromucosal glands were found to have recovered to normal condition. CONCLUSION: Weiwei san can increase the amount of intrinsic gastric gland and it has a satisfactory curative efficacy for CAG.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第21期1618-1619,共2页
China Pharmacy
关键词
慢性萎缩性胃炎
萎胃散
动物模型
Chronic atrophic gastritis
Weiwei san
Animal model